the aid library

Filter

2490

Ready to Use Therapeutic Food (RUFT) and the WHO Essential Medicines List

CMAM Forum (2018) CC

Severe Acute Malnutrition (SAM) is one of the greatest child survival challenges in the world today and reportedly affects more than 16.2 million children each year1. High impact, proven treatment interventions exist yet sadly approximately only 3.2 million children with SAM have access to treatme ... more

Download

View PDF

Responsible use of antibiotics in aquaculture

Hernández Serrano, P. Food and Agriculture Organization (FAO) (2005) C2

In aquaculture, antibiotics have been used mainly for therapeutic purposes and as prophylactic agents. The contribution to antimicrobial resistance of antibiotics used in aquaculture is reviewed here, using a risk analysis framework. Some recommenda ... more

Download

View PDF

Selection and Use of Essential Medicines 2021
recommended

World Health Organization WHO (2021) C_WHO

The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes ... more

Download

View PDF

Statement on the Use of Ivermectin for COVID-19

African Union; Africa CDC Centres for Disease Control and Prevention (2021) C1

Ivermectin is an antiparasitic drug approved for the treatment of parasitic infections, including strongyloidiasis and onchocerciasis in humans. There is a reported increase in the use of ivermectin for the prevention and treatment of COVID-19 by th ... more

Download

View PDF

Executive summary: the selection and use of essential medicines 2021

World Health Organization WHO (2021) C_WHO

Report of the 23rd WHO Expert Committee on the selection and use of essential medicines This executive summary reports the recommendations made by the Expert Committee for the 2021 update of the WHO Model List of Essential Medicines (EML) and the M ... more

External Link

Curbing Antimicrobial Resistance in Food Animal Production

Johns Hopkins Center for a Livable Future (2016) C2

Antimicrobials are widely used in food animal production, and use is rapidly increasing. In an era of growing demand for animal products, there is an increasing trend towards the industrial production of food animals, especially in lower- and middl ... more

Download

View PDF

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download

View PDF

Community- Based Management of Acute Malnutrition (CMAM)

World Vision International (2017) C1

Community-Based Management of Acute Malnutrition (CMAM) is a decentralised community-based approach to treating acute malnutrition. Treatment is matched to the nutritional and clinical needs of the child, with the majority children receiving treatment at home using ready-to- ... more

External Link

Current Treatments to Control African Trypanosomiasis and One Health Perspective

Venturelli, A.; Tagliazucchi, L.; Lima, C.; Venuti, F. MDPI Microorganisms (2022) CC

Human African Trypanosomiasis (HAT, sleeping sickness) and Animal African Trypanosomiasis (AAT) are neglected tropical diseases generally caused by the same etiological agent, Trypanosoma brucei. Despite important advances in the reduction or disappearance of HAT cases, AAT represents a risky reserv ... more

Download

View PDF

Fluid management of children with severe acute malnutrition with cholera

World Health Organization WHO (2017) C_WHO

The document provides WHO guidelines on fluid management for children with severe acute malnutrition (SAM) and cholera. It outlines protocols for rehydration therapy, including oral rehydration solutions (ORS) and intravenous fluids for cases of severe dehydration or shock. The guidelines emphasize ... more

Download

View PDF

Fluid management of children with severe acute malnutrition with cholera - Arabic version

World Health Organization WHO (2017) C_WHO

External Link

Combinations of Anti Malaria Drugs

Malaria Site (2015) C2

Combination therapy is a cornerstone of modern malaria treatment, particularly in the context of widespread multidrug resistance. Using two or more antimalarial drugs with different mechanisms simultaneously enhances efficacy, shortens treatment duration, improves compliance and delays the developme ... more

External Link

Asthma traeatment in children: A pragmatic approach

Masekela, R.; Jeevanathrum, A.; Kling, S.; et al. South African Medical Journal (2018) CC

Asthma is a heterogeneous condition characterised by chronic inflammation and variable expiratory airflow limitation, with airway reversibility. Management of chronic inflammation with anti-asthma medication improves asthma control and quality of life. The aim of this journal is to provide an eviden ... more

External Link

ANTIMICROBIAL RESISTANCE (AMR) AND MALARIA

World Health Organization WHO (2024) C_WHO

Antimicrobial resistance (AMR) and malaria remain significant public health challenges in the WHO Eastern Mediterranean Region (EMR). In 2021, the region reported 1.7 million sepsis-related deaths, with 373,000 associated with bacterial AMR. High antibiotic consumption, particularly in high-income c ... more

Download

View PDF

Considerations on the Use of Antivirals, Monoclonal Antibodies, and Other Interventions for the Management of COVID-19 Patients in Latin America and the Caribbean

World Health Organization WHO; PAHO; et al. (2022) CC

May 9, 2022.Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression to severe disease in people infected with SARS-CoV-2. Currently, ... more

Download

View PDF

Therapeutics and COVID-19: living guideline (Arabic)
recommended

World Health Organization WHO (2022) C_WHO

3 March 2022 The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf ... more

Download

View PDF

Therapeutics and COVID-19: living guideline, Updated 16 September 2022
recommended

World Health Organization WHO (2022) C_WHO

This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blocke ... more

Download

View PDF

Therapeutics for Ebola virus disease
recommended

World Health Organization WHO (2022) C_WHO

The WHO Ebola Virus Disease (EVD) Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with EVD. Providing guidance that is comprehensive and holistic for the optimal care of patients with EVD throughout their il ... more